Firebrick Pharma secures $732,000 through share placement

• Firebrick Pharma raised $732,000 via a placement of 20.9 million ordinary shares.
• The placement was priced at $0.035 per share, representing a 20.7% premium over the last traded price.
• Proceeds will fund US retail production, a new product launch in Singapore, and general working capital.

Firebrick Pharma (ASX:FRE) has secured $732,000 in firm commitments through a strategic placement of approximately 20.9 million fully paid ordinary shares to expand international distribution for its Nasodine franchise.

The transaction follows recent company announcements regarding plans to enter the US retail pharmacy market for Nasodine products.

Firebrick CEO and Executive Chairman, Peter Molloy stated, "Firebrick is very pleased to welcome this further investment from our licensing partner in the Philippines. It reflects an important commercial affirmation for the Nasodine franchise and should be seen as very encouraging by all shareholders."

The placement includes $631,750 from Philippine licensing partner Pharma Nutria N.A. Inc., increasing its stake to just over 10.0%, alongside $100,000 from an existing sophisticated investor.

The company will issue 18,050,000 shares under its 7.1A placement capacity and 2,857,142 shares under its 7.1 capacity, with final share issuance expected by 20 October 2026.

Following the announcement the Firebrick Pharma share price was unchanged at $0.031.

Firebrick operates as an Australian pharmaceutical developer focused on commercialising its Nasodine nasal spray across international markets.